LHF-535 / TuHURA Bio - LARVOL DELTA

The Biological Characteristics and Mouse Model of Lassa Virus From the First Imported Case in China. (PubMed, MedComm (2020)) - "Select the anti-LASV drug LHF-535 for preliminary evaluation, further confirming the stability of the model. In summary, the isolated strain exhibits enhanced transmission capabilities and may spread between mice via the respiratory tract, meriting greater attention and emphasis. This study will bridge the gap in China's independent P4-level pathogen isolation, meet national biosafety and strategic needs, and provide certain support for LASV research."

Journal • Preclinical • Hematological Disorders • Infectious Disease

Coadministration of ribavirin and arenaviral entry inhibitor LHF-535 enhances antiviral benefit against authentic Lassa virus. (PubMed, Virol Sin) - No abstract available

Journal

Coadministration of LHF-535 and favipiravir protects against experimental Junín virus infection and disease. (PubMed, Antiviral Res) - "The benefits of the drug combination were also evident by the absence of viremia and infectious virus in tissues compared to guinea pigs treated with only the placebos. Thus, combined targeting of JUNV-endosomal membrane fusion and the viral polymerase with pan-arenaviral LHF-535 and favipiravir may expand their indication beyond Lassa fever, providing a significant barrier to drug resistance."

Journal • Hematological Disorders • Infectious Disease

Lassa antiviral LHF-535 protects guinea pigs from lethal challenge. (PubMed, Sci Rep) - "A subset of surviving animals was rechallenged four months later with a second lethal challenge of Lassa virus and were found to be protected from disease. LHF-535 pharmacokinetics at the protective dose in guinea pigs showed plasma concentrations well within the range observed in clinical trials in healthy volunteers, supporting the continued development of LHF-535 as a Lassa therapeutic."

Journal • Infectious Disease

Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults. (PubMed, Antimicrob Agents Chemother) - "Treatment-emergent adverse events were more frequent in placebo recipients than in LHF-535 recipients in both studies. LHF-535 exhibited rapid absorption, a long half-life, and exposures predicted to suppress viral replication."

Journal • PK/PD data • Hematological Disorders • Infectious Disease

Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Kineta Inc.; Active, not recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Jun 2020

Clinical • Trial completion • Trial completion date

Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants (clinicaltrials.gov) - P1; N=32; Active, not recruiting; Sponsor: Kineta Inc.; Not yet recruiting ➔ Active, not recruiting

Clinical • Enrollment closed